Bernhard-Nocht-Str. 74, 20359 Hamburg
Tel.: +49-40-285380-367
Fax: 040-285380-281

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

Polack FP et al.N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.


Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.

Thomas SJ et al.N Engl J Med. 2021 Nov 4;385(19):1761-1773. doi: 10.1056/NEJMoa2110345. Epub 2021 Sep 15.


Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.

Frenck RW Jr et al.N Engl J Med. 2021 Jul 15;385(3):239-250. doi: 10.1056/NEJMoa2107456. Epub 2021 May 27.


One-year immunogenicity kinetics and safety of a purified chick embryo cell rabies vaccine and an inactivated Vero cell-derived Japanese encephalitis vaccine administered concomitantly according to a new, 1-week, accelerated primary series.

Cramer JP1Jelinek T2Paulke-Korinek M3Reisinger EC4Dieckmann S5Alberer M6Bühler S7Bosse D8Meyer S8Fragapane E9Costantini M9,Pellegrini M10Lattanzi M9Dovali C9.


Serological response following re-vaccination with Salmonella typhi Vi-capsular polysaccharide vaccines in healthy adult travellers.

Roggelin L1Vinnemeier CD2Fischer-Herr J3Johnson-Weaver BT4Rolling T5Burchard GD6Staats HF7Cramer JP8.


A 2013/2014 northern hemisphere season surface antigen inactivated trivalent influenza vaccine--Assessing the immunogenicity and safety in an open label, uncontrolled study.

Roggelin L1,2Vinnemeier CD1,2Meyer S3Witte K3Marx L2,4Theeß W2Burchard GD1,2Rolling T1,2Cramer JP1,2.


Evaluation of rabies immunogenicity and tolerability following a purified chick embryo cell rabies vaccine administered concomitantly with a Japanese encephalitis vaccine.

Jelinek T1Cramer JP2Dieckmann S3Hatz C4Paulke-Korinek M5Alberer M6Reisinger EC7Costantini M8Gniel D9Bosse D9Lattanzi M10.


Efficacy and safety of a patch vaccine containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase 3, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala.

Behrens RH1Cramer JP2Jelinek T3Shaw H4von Sonnenburg F5Wilbraham D6Weinke T7Bell DJ8Asturias E9Pauwells HL10Maxwell R11Paredes-Paredes M12Glenn GM13Dewasthaly S14Stablein DM15Jiang ZD16DuPont HL17.


Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®): an open label, uncontrolled study.

Vinnemeier CD1Fischer-Herr J1Meyer S2Liebig K2Theeß W3Burchard GD1Cramer JP1.


Efficacy of a travelers' diarrhea vaccine system in travelers to India.

Steffen R1Cramer JPBurchard GJelinek TSchwarz URamdas PChatterjee SJiang ZDDuPont HLDewasthaly SWestritschnig KBehrens RH.


Clinical relevance of different biomarkers in imported plasmodium falciparum malaria in adults: a case control study.

Stauga S1Hahn ABrattig NWFischer-Herr JBaldus SBurchard GDCramer JP.


A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations.

Hatz C1Cramer JPVertruyen ASchwarz TFvon Sonnenburg FBorkowski ALattanzi MHilbert AKCioppa GDLeroux-Roels G.


Influenza A(H1N1)pdm09 antibodies after pandemic and trivalent seasonal influenza vaccination as well as natural infection in November 2010 in Hamburg, Germany.

Cramer J1Mac THogan BStauga SEberhardt SWichmann OMertens TBurchard G.


Reduced cardiac output in imported Plasmodium falciparum malaria.

Herr J1Mehrfar PSchmiedel SWichmann DBrattig NWBurchard GDCramer JP.


Short-Term Immunogenicity and Safety of an Accelerated Pre-Exposure Prophylaxis Regimen With Japanese Encephalitis Vaccine in Combination With a Rabies Vaccine: A Phase III, Multicenter, Observer-Blind Study.

Jelinek T1Burchard GD2Dieckmann S3Bühler S4Paulke-Korinek M5Nothdurft HD6Reisinger E7Ahmed K8Bosse D9Meyer S9Costantini M10,Pellegrini M10.